"Tumours"

Science has published two consecutive research articles that suggest new ways to improve the efficacy of CAR-T for solid tumours.

For brain cancer, the major obstacle to treatment is not the tumour, but the brain itself. How to break the "blood-brain barrier" and allow effective anti-cancer drugs to enter the brain to take effect has long been a key issue in brain cancer treatment. Recently, a new study has shown that a new type of pump can be implanted in brain cancer patients to safely break the blood-brain barrier and better treat brain cancer!

According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.

Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).

PET/CT and PET/MRI, the world's leading-edge imaging screening devices, have extremely significant advantages in the early screening and diagnosis of a wide range of benign and malignant tumours throughout the body, the nervous system and the cardiovascular system, and can detect tumours as small as millimetres, especially useful for the early detection and treatment of liver cancer, breast cancer and pancreatic cancer. Translated with www.DeepL.com/Translator (free version)

CAR-T therapy is a cellular immunotherapy treatment that has become very popular in recent years. This therapy uses genetic engineering techniques to upgrade the patient's immune T cells in vitro, before entering the body to exert a powerful anti-cancer effect. Currently, CAR-T therapy has performed very well in blood cancers such as lymphoma and leukaemia.

A new study shows that for a common type of skin cancer, squamous cell carcinoma of the skin, immunotherapy before surgery resulted in the complete disappearance of tumours in 50.6% of patients and more than 90% in 12.7% of patients.

The US FDA has approved pemigatinib, the first targeted drug to date for patients with specific mutated blood tumours, and the results of the study show that the drug made tumours disappear completely in 79% of patients!